Editas Chief Medical Officer Gerald Cox to Depart at End of Year

Gerald Cox, chief medical officer of Editas Medicine (NASDAQ: [[ticker:EDIT]]), will step down at the end of 2018, the gene editing company announced Monday, after the markets closed. Cambridge, MA-based Editas gave no reason for Cox’s departure, but said that a search for his successor is underway. Cox joined Editas in 2016, a few months after the company went public. Editas is working to advance its lead program, an experimental treatment for a rare, inherited form of blindness called Leber congenital amaurosis, into clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.